Published US analyses find 39 to 65 percent of adults taking GLP-1 medications for weight management discontinue within the first year. Stramesis gives your clinic the intelligence to change that.
Sources: Marshall et al., J Manag Care Spec Pharm, 2026; Rodriguez et al., JAMA Netw Open, 2025.
GLP-1 dropout rarely comes out of nowhere. The warning signs are usually there weeks before a patient disappears. Most clinics are simply not set up to see them in time.
Stramesis runs in the background of your clinic every day. Each morning your team sees which patients may need outreach and the likely reason.
Most tools in the GLP-1 space are built for patients or for pharmaceutical brands. Stramesis is built for the clinic operations layer, where retention actually fails and where revenue is being lost.
We walk you through the platform using your clinic's actual patient volume and revenue numbers. You will see exactly what Stramesis looks like for your practice.